The fading relevance of the quantity of brain metastases in patients with non-small cell lung cancer

Autor: Reinecke, D, Jünger, ST, Kocher, M, Nogova, L, Eich, ML, Ruge, MI, Rueß, D, Goldbrunner, R, Grau, S

Publikováno v: 73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie; 20220529-20220601; Köln; DOCV164 /20220525/

Objective: That the number of brain metastases (BM) is included in prognostic assessment models for patients with non-small cell lung cancer (NSCLC). However, the underlying data were generated in an era with limited systemic treatment options. With

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bb92307c14b78abd87376fd85a9ce44

Solitary fibrous tumor of the prostate with accompanying low-grade prostate cancer.

Autor: Eich ML; Institute of Pathology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humbolt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany., Furlano K; Department of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany., Hilfenhaus G; Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Ralla B; Department of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany., Keilholz U; Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center, Heidelberg, Germany., Joosten M; Institute of Pathology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humbolt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany., Rieke DT; Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center, Heidelberg, Germany., Schlomm T; Department of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany., Horst D; Institute of Pathology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humbolt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center, Heidelberg, Germany., Schallenberg S; Institute of Pathology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humbolt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.

Publikováno v: Urology case reports [Urol Case Rep] 2024 Nov 06; Vol. 57, pp. 102879. Date of Electronic Publication: 2024 Nov 06 (Print Publication: 2024).

Blocking the angiopoietin-2-dependent integrin β-1 signaling axis abrogates small cell lung cancer invasion and metastasis.

Autor: Meder L; Friedrich-Alexander-Universität Erlangen-Nürnberg, Faculty of Medicine, Department of Experimental Medicine 1, Erlangen, Germany.; Mildred Scheel School of Oncology and., Orschel CI; Mildred Scheel School of Oncology and.; Department I of Internal Medicine, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany., Otto CJ; Mildred Scheel School of Oncology and.; Department I of Internal Medicine, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany., Koker M; Department I of Internal Medicine, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany., Brägelmann J; Mildred Scheel School of Oncology and.; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.; Department of Translational Genomics and., Ercanoglu MS; Institute of Virology, Laboratory of Experimental Immunology, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany., Dähling S; Institute of Virology, Laboratory of Experimental Immunology, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany., Compes A; Mildred Scheel School of Oncology and.; Department I of Internal Medicine, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany., Selenz C; Department I of Internal Medicine, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany., Nill M; Department I of Internal Medicine, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany., Dietlein F; Department of Medical Oncology, Dana-Faber Cancer Institute, Boston, Massachusetts, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Florin A; Institute for Pathology, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany., Eich ML; Institute for Pathology, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany., Borchmann S; Department I of Internal Medicine, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany.; Else Kröner Forschungskolleg Clonal Evolution in Cancer, University Hospital Cologne, Cologne, Germany.; German Hodgkin Study Group, Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany., Odenthal M; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.; Institute for Pathology, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany., Blazquez R; University Hospital Regensburg, Department of Internal Medicine III, Hematology and Medical Oncology, Regensburg, Germany., Hilberg F; Department of Pharmacology, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Klein F; Institute of Virology, Laboratory of Experimental Immunology, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany., Hallek M; Department I of Internal Medicine, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany., Büttner R; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.; Institute for Pathology, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany., Reinhardt HC; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, German Cancer Consortium (DKTK), Essen, Germany., Ullrich RT; Mildred Scheel School of Oncology and.; Department I of Internal Medicine, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany.

Publikováno v: JCI insight [JCI Insight] 2024 May 22; Vol. 9 (10). Date of Electronic Publication: 2024 May 22.

Impact of FAPI-46/dual-tracer PET/CT imaging on radiotherapeutic management in esophageal cancer.

Autor: Wegen S; Department of Radiation Oncology, Cyberknife and Radiotherapy, Faculty of Medicine, University Hospital Cologne, Cologne, Germany. simone.wegen@uk-koeln.de.; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany. simone.wegen@uk-koeln.de., Claus K; Department of Radiation Oncology, Cyberknife and Radiotherapy, Faculty of Medicine, University Hospital Cologne, Cologne, Germany.; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany., Linde P; Department of Radiation Oncology, Cyberknife and Radiotherapy, Faculty of Medicine, University Hospital Cologne, Cologne, Germany.; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany., Rosenbrock J; Department of Radiation Oncology, Cyberknife and Radiotherapy, Faculty of Medicine, University Hospital Cologne, Cologne, Germany.; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany., Trommer M; Department of Radiation Oncology, Cyberknife and Radiotherapy, Faculty of Medicine, University Hospital Cologne, Cologne, Germany.; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.; Department of Radiation Oncology, Olivia Newton-John Cancer Wellness & Research Centre, Austin Health, Melbourne, Australia., Zander T; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.; Department I of Internal Medicine, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany., Tuchscherer A; Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.; Department I of Internal Medicine, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany., Bruns C; Department of General, Visceral, Cancer and Transplantation Surgery, Faculty of Medicine, with University Hospital Cologne, Cologne, Germany., Schlößer HA; Department of General, Visceral, Cancer and Transplantation Surgery, Faculty of Medicine, with University Hospital Cologne, Cologne, Germany.; Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Schröder W; Department of General, Visceral, Cancer and Transplantation Surgery, Faculty of Medicine, with University Hospital Cologne, Cologne, Germany., Eich ML; Institute of Pathology, Faculty of Medicine, University Hospital Cologne, Cologne, Germany., Fischer T; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Schomäcker K; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Drzezga A; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Institute of Neuroscience and Medicine, Molecular Organization of the Brain, Forschungszentrum Jülich, INM-2, Cologne, Germany., Kobe C; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Roth KS; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Weindler JJ; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Publikováno v: Radiation oncology (London, England) [Radiat Oncol] 2024 Apr 04; Vol. 19 (1), pp. 44. Date of Electronic Publication: 2024 Apr 04.

HoLy-Net: Segmentation of histological images of diffuse large B-cell lymphoma.

Autor: Naji H; Institute for Biomedical Informatics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany. Electronic address: hnaji@uni-koeln.de., Sancere L; Institute for Biomedical Informatics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany., Simon A; Institute of Pathology, University Hospital Cologne, Germany., Büttner R; Institute of Pathology, University Hospital Cologne, Germany., Eich ML; Institute of Pathology, University Hospital Cologne, Germany., Lohneis P; Institute of Pathology, University Hospital Cologne, Germany; Hämatopathologie Lübeck, Germany., Bożek K; Institute for Biomedical Informatics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Germany.

Publikováno v: Computers in biology and medicine [Comput Biol Med] 2024 Mar; Vol. 170, pp. 107978. Date of Electronic Publication: 2024 Jan 11.